Publication:
Prediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study

dc.contributor.authorÇetintaş, Sibel
dc.contributor.authorTezcan, Gülçin
dc.contributor.authorTunca, Berrin
dc.contributor.authorEgeli, Ünal
dc.contributor.authorGökgöz, Mustafa Şehsuvar
dc.contributor.authorÇecener, Gülsah
dc.contributor.buuauthorÇETİNTAŞ, SİBEL
dc.contributor.buuauthorTUNCA, BERRİN
dc.contributor.buuauthorEGELİ, ÜNAL
dc.contributor.buuauthorGÖKGÖZ, MUSTAFA ŞEHSUVAR
dc.contributor.buuauthorÇEÇENER, GÜLŞAH
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGenel Cerrahi Ana Bilim Dalı
dc.contributor.orcid0000-0002-1619-6680
dc.contributor.orcid0000-0001-7904-883X
dc.contributor.orcid0000-0002-3820-424X
dc.contributor.researcheridEWY-5692-2022
dc.contributor.researcheridAAA-7047-2020
dc.contributor.researcheridAAH-1420-2021
dc.contributor.researcheridABI-6078-2020
dc.contributor.researcheridAAP-9988-2020
dc.date.accessioned2024-11-20T05:54:55Z
dc.date.available2024-11-20T05:54:55Z
dc.date.issued2019-01-01
dc.description.abstractDistant organ tumor dissemination is a major cause of breast cancer-related deaths. In 2010, we analyzed the prognostic importance of the circulating tumor markers (CTMs) cytokeratin 19 (CK19), CK20, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in relation to the clinical and pathological characteristics of patients with breast cancer (BC). To assess the clinical utility of CK19, CK20 and EGFR in predicting distant metastasis in BC, here we report 7-year follow-up results of 77 patients. The patients with at least one positive CTM were classified as CTM(+) and those negative for all CTMs were assigned to CTM(-) group. In patients who received no treatment following CTM analysis, 25.0% had metastasis in CTM(+) and 10.0% in CTM(-) group. In patients who received one of the following therapies: chemotherapy, radiotherapy or hormone therapy, or the combinations of these therapies, the rate of metastasis was 33.3% in CTM(+) and 20.0% in CTM(-) group. Disease-free time was shorter in CTM(+) patients compared to CTM(-) group (28.83 +/- 10.76 and 41.38 +/- 9.5 months, respectively). According to multivariate Cox proportional hazard regression analysis, the presence of regional lymph node metastasis, Ki-67 expression, higher tumor grade and CTM expression status were predictors of poor prognosis associated with distant metastasis (p < 0.05). Also, CTM positivity was a factor associated with metastasis-related poor prognosis (HR = 0.492, p = 0.026). The mean survival for CTM(+) patients was shorter than that for CTM(-) patients (90.671 +/- 2.66 and 101.23 +/- 3.92 months, respectively; p > 0.05). Our findings demonstrate that CTM positivity may indicate a high metastasis risk; however, CTM negativity does not guarantee low metastasis risk. These results may encourage further preclinical investigation of CTMs, to evaluate the possible implications of these findings to the clinical setting.
dc.identifier.doi10.17305/bjbms.2018.3371
dc.identifier.endpage179
dc.identifier.issn1512-8601
dc.identifier.issue2
dc.identifier.startpage172
dc.identifier.urihttps://doi.org/10.17305/bjbms.2018.3371
dc.identifier.urihttps://www.bjbms.org/ojs/index.php/bjbms/article/view/3371
dc.identifier.urihttps://hdl.handle.net/11452/48155
dc.identifier.volume19
dc.identifier.wos000468754400008
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo
dc.relation.journalBosnian Journal of Basic Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBone metastases
dc.subjectClinical-features
dc.subjectPeripheral-blood
dc.subjectCells
dc.subjectCk20
dc.subjectCk19
dc.subjectEgfr
dc.subjectBreast cancer
dc.subjectCirculating tumor cell markers
dc.subjectMetastasis
dc.subjectResearch & experimental medicine
dc.titlePrediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Radyasyon Onkolojisi Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Tıbbi Biyoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Genel Cerrahi Ana Bilim Dalı
relation.isAuthorOfPublicationb430e050-0446-4b11-8cf7-9ac5d9768bc0
relation.isAuthorOfPublication121a3732-be5d-4aff-9195-357c8347daca
relation.isAuthorOfPublication051cf631-d214-4c8f-b1f5-fa1d27d5269c
relation.isAuthorOfPublication7b478372-ad3a-4f0a-a336-3ebde58856eb
relation.isAuthorOfPublicationae26ce61-4a33-4336-9fe3-b40d1138c397
relation.isAuthorOfPublication.latestForDiscoveryb430e050-0446-4b11-8cf7-9ac5d9768bc0

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cetintas_vd_2019.pdf
Size:
306.94 KB
Format:
Adobe Portable Document Format